硼替佐米、地塞米松联合环磷酰胺治疗骨髓瘤的临床疗效及对患者不良反应发生的影响

Clinical efficacy of bortezomib,dexamethasone combined with cyclophosphamide in the treatment of myeloma and its effect on the occurrence of adverse reactions in patients

目的探究硼替佐米、地塞米松联合环磷酰胺治疗骨髓瘤的疗效及对患者不良反应发生的影响。方法研究对象为我院2016年1月—2020年12月收治的60例骨髓瘤患者,将其随机分为研究1组(n=20)、研究2组(n=20)与对照组(n=20)。对照组给予硼替佐米联合沙利度胺及地塞米松化疗,研究1组给予硼替佐米联合环磷酰胺及地塞米松化疗,研究2组给予硼替佐米联合来那度胺及地塞米松化疗。对比三组治疗效果、免疫功能变化情况、相关血清因子水平以及骨代谢因子水平变化情况。结果对照组治疗有效率85.0%比研究1组95.0%、研究2组90.0%低(P<0.05);三组治疗前的免疫对比无较大差异(P>0.05),对照组经治疗后的免疫功能比研究组差(P<0.05);三组治疗前的相关血清因子水平比较无较大差异(P>0.05),对照组经治疗后的相关血清因子水平比研究1组、研究2组高(P<0.05);对照组经治疗后的骨代谢因子水平变化比研究1组、研究2组差(P<0.05)。结论硼替佐米、地塞米松联合环磷酰胺治疗骨髓瘤效果理想,药物不良反应发生率下降,患者生活质量得到改善,可在临床推广应用。

Objective To investigate the clinical efficacy of bortezomib,dexamethasone combined with cyclophosphamide in the treatment of myeloma and the effect on the occurrence of adverse reactions in patients.Methods The subjects were 60 myeloma patients admitted to our hospital from January 2016 to December 2020,and they were randomly divided into study group 1(n=20),study group 2(n=20)and control group(n=20).The control group received bortezomib combined with thalidomide and dexamethasone chemotherapy,the study group 1 received bortezomib combined with cyclophosphamide and dexamethasone chemotherapy,and the study group 2 received bortezomib combined with lenalidomide and dexamethasone chemotherapy.The therapeutic efficacy,the changes of immune function,serum factors and bone metabolism factors were compared among the three groups.Results The effective rate of control group was 85.0%,which was lower than those of study group 1 and study group 2(P<0.05).There was no significant difference of immune function among the three groups before treatment(P>0.05),which of the control group after treatment was worse than that of the study groups(P<0.05).There were no significant differences in the levels of related serum factors among the three groups before treatment(P>0.05),which in the control group after treatment was higher than those in the study group 1 and study group 2(P<0.05).After treatment,the changes of bone metabolic factors in control group were worse than those in study group 1 and study group 2(P<0.05).Conclusion Bortezomib,dexamethasone combined with cyclophosphamide in the treatment of myeloma had ideal effect,and the incidence of adverse drug reaction was reduced,the quality of life of patients was improved,which can be popularized in clinical application.